(4,5-Dimethyl-6-morpholin-4-yl-pyridazin-3-yl)-(2,5-dimethyl-pyrrol-1-yl)-amine | 89937-43-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (4,5-Dimethyl-6-morpholin-4-yl-pyridazin-3-yl)-(2,5-dimethyl-pyrrol-1-yl)-amine
• 英文别名: N-(2,5-dimethylpyrrol-1-yl)-4,5-dimethyl-6-morpholin-4-ylpyridazin-3-amine
• CAS: 89937-43-9
• 化学式: C₁₆H₂₃N₅O
• 分子量: 301.392
• InChiKey: QSOQBIGUDHPFSM-UHFFFAOYSA-N

物化性质

• 沸点：
  545.8±60.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  55.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3,6-二氯-4,5-二甲基哒嗪 在 一水合肼 作用下， 以 溶剂黄146 为溶剂， 反应 13.5h， 生成 (4,5-Dimethyl-6-morpholin-4-yl-pyridazin-3-yl)-(2,5-dimethyl-pyrrol-1-yl)-amine
  参考文献：
  名称：

  Antihypertensives. N-1H-Pyrrol-1-yl-3-pyridazinamines

  摘要：

  The hypothesis that the side effects of hydralazine, such as mutagenicity and lupus erythematosus like syndrome, might be due to the NHNH2 group prompted us to incorporate part of this moiety into a pyrrole ring. Therefore, we prepared a series of N-1H-pyrrol-1-yl-3-pyridazinamines and a limited number of N-1H-pyrrol-1-yl-1-phthalazinamines by reaction of 3-hydrazinopyridazines and 1-hydrazinophthalazines with gamma-diketones. Most of these compounds, especially in the pyridazine series, showed moderate to strong antihypertensive activity in spontaneously hypertensive rats. The decrease in blood pressure generally had a slow onset after either oral or intravenous administration. N-(2,5-Dimethyl-1H-pyrrol-1-yl)-6-(4-morpholinyl)-3-pyridazinamine hydrochloride (30) (MDL 899) showed no mutagenic activity in several tests and is now in clinical trials in patients.

  DOI：

  10.1021/jm00374a024

文献信息

• Antihypertensives. N-1H-Pyrrol-1-yl-3-pyridazinamines
  作者：Elvio Bellasio、Ambrogio Campi、Nunzio Di Mola、Emiliana Baldoli

  DOI：10.1021/jm00374a024

  日期：1984.8

  The hypothesis that the side effects of hydralazine, such as mutagenicity and lupus erythematosus like syndrome, might be due to the NHNH2 group prompted us to incorporate part of this moiety into a pyrrole ring. Therefore, we prepared a series of N-1H-pyrrol-1-yl-3-pyridazinamines and a limited number of N-1H-pyrrol-1-yl-1-phthalazinamines by reaction of 3-hydrazinopyridazines and 1-hydrazinophthalazines with gamma-diketones. Most of these compounds, especially in the pyridazine series, showed moderate to strong antihypertensive activity in spontaneously hypertensive rats. The decrease in blood pressure generally had a slow onset after either oral or intravenous administration. N-(2,5-Dimethyl-1H-pyrrol-1-yl)-6-(4-morpholinyl)-3-pyridazinamine hydrochloride (30) (MDL 899) showed no mutagenic activity in several tests and is now in clinical trials in patients.